Novel Oral Anticoagulants at 10: An Assessment of their Safety and Contemporary Use in Atrial Fibrillation

Published: 04 March 2021

  • Views:

    Views Icon 10765
  • Likes:

    Heart Icon 1

Overview

Full programme

  • Views:

    Views Icon 10765
  • Likes:

    Heart Icon 1

Overview

In this virtual roundtable, our expert panel reflect on the clinical trials and real world data supporting the use of NOACs in atrial fibrillation – almost ten years since they entered the clinic.

Moderated by Prof John Eikelboom, the panel offer their analyses via a series of presentations and discussions covering a range of topics, with a special focus on their use in Japan.

This activity has been supported via an educational grant from Boehringer Ingelheim

Learning Objectives

  • Identify which individuals with atrial fibrillation should be initiated on NOAC therapy without delay
  • Interpret safety and cardiovascular data from RCTs in the context of real-world experience
  • Select appropriate treatment strategies with NOACs in atrial fibrillation patients in need of further ablation or intervention
  • Review the reversal options open to individuals experiencing a bleeding event whilst on treatment with a NOAC

Target Audience

  • Cardiologists
  • Interventional Cardiologists

Series overview

Part 1

When to Initiate a NOAC and Patient Suitability (data presentation)

An overview of current guidelines

1 session

Part 2

Overview of Safety and Cardiovascular Data

a. Safety and cardiovascular data from RCTs b. Real-world and meta-analyses

1 session

Part 3

Dealing with Complications:

Major bleeding events and reversal

1 session

Part 4

Discussion on Safety Rates and Patient Suitability (Panel Discussion Session)

Panel recommendations of NOAC choice according to different patient populations

1 session

  • Panel discussion moderated by John Eikelboom

    Watch now

Part 5

NOAC Use with Ablation and Intervention

a. Guideline recommendations and current trends b. Use of NOACs with ablation in Japan: clinical data

1 session

Part 6

Discussion on the Current Use of NOACs in Japan

a. Use in elderly/very old pts b. Under-dosing of NOACs c. Current unmet needs

1 session

  • Panel Discussion Moderated by John Eikelboom

    Watch now

Faculty biographies